Most antibody drugs treat cancer and autoimmune diseases, and many of the rest are used to treat orphan and infectious diseases. Unfortunately, antibodies are complex proteins in many ways, which complicates their purification and characterization, making it difficult for their developers to meet the rigid requirements for therapeutics. Process development scientists, faced with an…
IDST Monthly Access Membership Required
You must be a IDST Monthly Access member to access this content.
IDST Pro Access Required
This analysis is part of IDST premium intelligence.
Subscribe to Continue ReadingAlready a member? Log in